Abstract:Schematic illustration of a large‐scale fabrication strategy is presented for producing ultra‐stable 177Lu coordinated phosphorylcholine‐modified polymeric microspheres via a novel ESP‐RIGP technology. The 177Lu loading process involves the formation of a stable complex through cooperative ligand complexation of three phosphorylcholines, which synergistically enhances the radiostability of 177Lu‐PCMs based on hydrogen bonding‐mediated hydration layer. 177Lu‐PCMs display high radiostability, excellent mechanical properties, good hydrophilicity, and controlled sphere size, which can meet the needs of clinical precision intravascular brachytherapy. These studies demonstrate the safety and theranostic efficacy of 177Lu‐PCMs as an ultra‐stable embolic agent for intra‐arterial brachytherapy in rat N1S1, rabbit VX2 liver tumor, pig, and isolated human liver tumor tissue models. Intravascular brachytherapy requires advances in radio‐embolization technologies that combine brilliant radiostability efficacy with a facile and green synthesis route. A hybrid‐integrated radioactive microsphere strategy using phosphorylcholine‐modified lutetium‐177 coordinated polymeric microspheres (177Lu‐PCMs) is reported that are fabricated via radiation‐induced graft polymerization for imaging‐guided locoregional intravascular brachytherapy. The underlying formation mechanism of 177Lu‐PCMs is elucidated using first‐principles computations and density functional theory calculations, and 177Lu loading mechanisms are investigated with Near‐edge and extended X‐ray absorption fine structure spectroscopy. The engineered 177Lu‐PCMs exhibit excellent mechanical properties, good hydrophilicity, and controlled sphere diameter. These features provide advantages of ultra‐stable embolic radio‐theranostics, which is demonstrated in different preclinical rodent models and isolated human liver tumor tissues. During locoregional intra‐arterial brachytherapy, 177Lu‐PCMs can be visualized via SPECT to validate the in vivo biodistribution and retention in real time, achieving precise delivery, effective anti‐cancer treatment, and a distinguished safety profile without degradation, ectopic embolization, and adverse reactions. Therefore, this study offer a new avenue for the development of a highly innovative and translational approach for precision intra‐arterial brachytherapy.

Imageable Brachytherapy with Chelator‐Free Radiolabeling Hydrogel

Radiosensitizer-based Injectable Hydrogel for Enhanced Radio-Chemotherapy of TNBC

Near-Infrared-Triggered in Situ Gelation System for Repeatedly Enhanced Photothermal Brachytherapy with a Single Dose.

Pioneering Iodine-125-Labeled Nanoscale Covalent Organic Frameworks for Brachytherapy

Preclinical evaluation of cationic DOTA-triarginine-lipid conjugates for theranostic liquid brachytherapy

Ultra-small Iron-Gallic Acid Coordination Polymer Nanoparticles for Chelator-Free Labeling of 64cu and Multimodal Imaging-Guided Photothermal Therapy

Multifunctional Hybrid Hydrogel Enhanced Antitumor Therapy through Multiple Destroying DNA Functions by a Triple‐Combination Synergistic Therapy

Cluster Missile‐Inspired Dynamic Nanocomposite Hydrogel Precisely Mediates Robust Locoregional Tumor Theranostics

Renal-Clearable Ultrasmall Coordination Polymer Nanodots for Chelator-Free 64Cu-Labeling and Imaging-Guided Enhanced Radiotherapy of Cancer.

Tumor‐Targeted Injectable Double‐Network Hydrogel for Prevention of Breast Cancer Recurrence and Wound Infection via Synergistic Photothermal and Brachytherapy

Engineering Radioactive Microspheres for Intra‐Arterial Brachytherapy Using Radiation‐Induced Graft Polymerization

Fluorescent Realgar Nanoclusters for Nuclear Targeting-Triggered Tumor Theranostics

Nanoengineered Injectable Hydrogel: An Advanced Radioprotective Barrier with Magnetic Hyperthermia Synergy

Biocompatible Conjugated Polymer Nanoparticles Labeled with 225 Ac for Tumor Endoradiotherapy

Design of Phase-Changeable and Injectable Alginate Hydrogel for Imaging-Guided Tumor Hyperthermia and Chemotherapy

A Ph-Responsive Hydrogel Based on a Tumor-Targeting Mesoporous Silica Nanocomposite for Sustained Cancer Labeling and Therapy.

Multimodal Imaging-Guided Strategy for Developing 177Lu-Labeled Metal-Organic Framework Nanomedicine with Potential in Cancer Therapy

Fluoropolymer-MOF Hybrids with Switchable Hydrophilicity for 19F MRI-Monitored Cancer Therapy.

Development of in situ forming thermosensitive hydrogel for radiotherapy combined with chemotherapy in a mouse model of hepatocellular carcinoma

Ph-Sensitive Gold Nanoclusters Labeling with Radiometallic Nuclides for Diagnosis and Treatment of Tumor

Sub‐50 nm Supramolecular Nanohybrids with Active Targeting Corona for Image‐Guided Solid Tumor Treatment and Metastasis Inhibition